Clinical trials: Melanoma Stage
Malignant Melanoma
Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC
Evaluation of the efficacy, safety and biologic effects of neo-adjuvant treatment with vemurafenib + cobimetinib + atezolizumab in patients with limited metastasis of melanoma in stage IIIC/IV melanoma.
- Trial name
- NEO-VC (NCT02303951)
- Testing
- Vemurafenib, Cobimetinib, Atezolizumab
- Where
- 7 sites in France, Germany
- Volunteers
- 47 people
- Sponsor
- University Hospital Tuebingen
Malignant Melanoma
Lapatinib in Stage IV Melanoma With ERBB4 Mutations
Background: Studies of melanoma tumor samples have shown that tumor cells from approximately 20 percent of melanoma patients contain a specific mutation of a gene involved in making a protein called ERBB4, and that changes in…
- Trial name
- NCT01264081
- Testing
- Lapatinib
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- National Cancer Institute (NCI)
Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8
The Impact of an Antibiotic (Cefazolin) Before Surgery on the Microbiome in Patients With Stage I-II Melanoma
This phase I trial investigates the impact of cefazolin before surgery on the microbiome in patients with stage I-II melanoma. Antibiotics, such as cefazolin, given at the time of surgery may cause a significant change in the…
- Conditions
- Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage IA Cutaneous Melanoma AJCC v8, Clinical Stage IB Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8
- Trial name
- NCT04875728
- Testing
- Cefazolin, Resection
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- M.D. Anderson Cancer Center
Melanoma
Nivolumab, BMS-936558 in Combination With Relatlimab, BMS-986016 in Patients With Metastatic Melanoma Naïve to Prior Immunotherapy in the Metastatic Setting
The main goal of this study is to evaluate the antitumor activity of relatlimab and nivolumab in combination in subjects with unresectable or metastatic melanoma who have not received prior treatment with immunotherapy.
- Trial name
- NCT03743766
- Testing
- Relatlimab, Nivolumab, Relatlimab + Nivolumab
- Where
- United States
- Volunteers
- 43 people
- Sponsor
- John Kirkwood
Melanoma, Renal Carcinoma
A Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of JS004 in Advanced Solid Tumors
An open-label, dose-escalation, phase I clinical study to evaluate the safety and tolerability of JS004 injection in the patients with advanced solid tumors who have failure in standard of care and are unable to tolerate standard…
- Conditions
- Melanoma, Renal Carcinoma, Urothelial Carcinoma
- Trial name
- NCT04773951
- Testing
- JS004, a recombinant humanized, IgG4κ monoclonal antibody (mAb) specific to B- and T-lymphocyte attenuator (BTLA); Toripalimab Injection
- Where
- 11 sites in China
- Volunteers
- 47 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC
Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors
The purpose of this first in human (FIH) trial was to characterize the safety and tolerability of the SHP2 inhibitor TNO155 alone and in combination with EGF816 (nazartinib) and identify a recommended dose for future studies in…
- Conditions
- Advanced EGFR Mutant Non Small Cell LungCancer (NSCLC), KRAS G12-mutant NSCLC, Esophageal Squamous Cell Cancer (SCC), Head/Neck SCC
- Trial name
- NCT03114319
- Testing
- TNO155, TNO155 in combination with EGF816 (nazartinib)
- Where
- 18 sites in United States, Canada and 7 more
- Volunteers
- 227 people
- Sponsor
- Novartis Pharmaceuticals
Metastatic Solid Tumor, Colon Cancer
Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With CRC, NSCLC, and STS
The goal of this clinical trial is to determine the safety and efficacy of IP-001 for intratumoral injection administration following thermal ablation of a solid tumor.
- Conditions
- Metastatic Solid Tumor, Colon Cancer, Nonsmall Cell Lung Cancer, Soft Tissue Sarcoma
- Trial name
- INJECTABL-1 (NCT05688280)
- Testing
- 1.0% IP-001 for Injection
- Where
- 16 sites in United States, France and 3 more
- Volunteers
- 42 people
- Sponsor
- Immunophotonics, Inc.
Metastatic Melanoma, Head and Neck Squamous Cell Carcinoma
GR-MD-02 + Pembrolizumab Versus Pembrolizumab Monotherapy in Melanoma and Squamous Cell Head and Neck Cancer Patients
The purpose of this study is to test the safety \& efficacy of combination drugs versus placebo to treat metastatic melanoma and head and neck squamous cell carcinoma.
- Trial name
- NCT04987996
- Testing
- GR-MD-02, Pembrolizumab
- Where
- United States
- Sponsor
- Providence Health & Services
Pancreatic Cancer, Melanoma
Immunotherapy Study of Evofosfamide in Combination With Ipilimumab
An immunotherapy study combining ipilimumab and evofosfamide for the treatment of patients with confirmed metastatic or locally advanced prostate cancer, metastatic pancreatic cancer, melanoma or human papillomavirus (HPV)…
- Conditions
- Pancreatic Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Prostate Cancer
- Trial name
- NCT03098160
- Testing
- Evofosfamide, Ipilimumab
- Where
- United States
- Volunteers
- 69 people
- Sponsor
- Threshold Pharmaceuticals
Progressive Metastatic Malignancies
Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic Malignancies
This is a Phase 1, open-labeled, non-randomized, multi-center, competitive enrollment and dose-escalation study of ALT-801, the study drug.
- Trial name
- NCT00496860
- Testing
- ALT-801
- Where
- 4 sites in United States
- Volunteers
- 26 people
- Sponsor
- Altor BioScience
Breast Cancer, Non-small Cell Lung Cancer
A Study of Abemaciclib (LY2835219) in Participants With Breast Cancer, Non-small Cell Lung Cancer, or Melanoma That Has Spread to the Brain
The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as abemaciclib in participants with hormone receptor positive breast cancer, non-small cell lung cancer (NSCLC), or melanoma that…
- Conditions
- Breast Cancer, Non-small Cell Lung Cancer, Melanoma, Brain Metastases
- Trial name
- NCT02308020
- Testing
- Abemaciclib
- Where
- 44 sites in United States, Australia and 7 more
- Volunteers
- 162 people
- Sponsor
- Eli Lilly and Company
Melanoma, Non Small Cell Lung Cancer
A Study of NIVO Plus IPI and Guadecitabine or NIVO Plus IPI in Melanoma and NSCLC Resistant to Anti-PD1/PDL1
This is a run-in, randomized, non-comparative, phase II study designed according to a two stages optimal design by Simon. This phase II design will be preceded by a safety evaluation after the first cohort of 6 patients to…
- Trial name
- NIBIT-ML1 (NCT04250246)
- Testing
- Ipilimumab plus nivolumab plus guadecitabine, Ipilimumab plus nivolumab
- Where
- Italy
- Volunteers
- 184 people
- Sponsor
- Italian Network for Tumor Biotherapy Foundation
Cancer
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
BRF113683 is a Phase III, randomized, open-label study comparing the efficacy, safety, and tolerability of GSK2118436 to dacarbazine (DTIC), in subjects with BRAF mutant advanced (Stage III) or metastatic (Stage IV) melanoma.
- Trial name
- NCT01227889
- Testing
- GSK2118436, Dacarbazine (DTIC)
- Where
- 94 sites in United States, Australia and 10 more
- Volunteers
- 251 people
- Sponsor
- GlaxoSmithKline
Melanoma, Stage II, HER2-positive
A Study of RC48-ADC in Advanced Melanoma Subjects With HER2 Variant (Mutation, Amplification, Overexpression)
This is a Phase IIa, single-arm, multicentre, open-label clinical trial aims to evaluate the effectiveness and safety of RC48-ADC in the treatment of HER2 Variant (Mutation, Amplification, Overexpression) advanced melanoma.
- Conditions
- Melanoma, Stage II, HER2-positive, Advanced Melanoma
- Trial name
- NCT05135715
- Testing
- RC48-ADC
- Where
- 4 sites in China
- Volunteers
- 50 people
- Sponsor
- RemeGen Co., Ltd.
Cancer of Colon, Malignant Melanoma
IVIG in the Treatment of Metastatic Cancers of the Prostate, Colon and Melanoma
The purpose of this study is to evaluate the safety and efficacy of IVIG in the treatment of metastatic cancer of the prostate, colon and melanoma.
- Conditions
- Cancer of Colon, Malignant Melanoma, Urologic Cancer
- Trial name
- NCT00294476
- Testing
- IVIG, Biological Therapy
- Where
- 3 sites in Israel
- Volunteers
- 30 people
- Sponsor
- GammaCan
Melanoma
Safety and Efficacy Study of Electrotransfer of Plasmid AMEP to Treat Advanced or Metastatic Melanoma
The objective of the present trial is to evaluate the local and general safety of the intratumoural electrotransfer of increasing doses of Plasmid AMEP in patients suffering from advanced or metastatic melanoma and to identify…
- Trial name
- AMEP (NCT01045915)
- Testing
- naked DNA coding for protein AMEP
- Where
- 3 sites in Denmark, France and 1 more
- Volunteers
- 5 people
- Sponsor
- Valerio Therapeutics
Melanoma (Skin)
Indomethacin Plus Biological Therapy in Treating Patients With Advanced Melanoma
RATIONALE: Biological therapies use different ways to stimulate the immune system and stop tumor cells from growing. Combining biological therapies with indomethacin and cyclophosphamide may kill more tumor cells.
- Trial name
- NCT00002535
- Testing
- aldesleukin, lymphokine-activated killer cells, therapeutic tumor infiltrating lymphocytes
- Where
- United States
- Sponsor
- St. Luke's Medical Center
Breast Cancer, Lung Cancer
Ontario-wide Cancer TArgeted Nucleic Acid Evaluation
Substantial progress has been made in the treatment of cancer through the use of targeted therapies, but what works for one patient might not work for another patient.
- Conditions
- Breast Cancer, Lung Cancer, Colorectal Cancer, Melanoma
- Trial name
- OCTANE (NCT02906943)
- Where
- 7 sites in Canada
- Volunteers
- 10,000 people
- Sponsor
- University Health Network, Toronto
Melanoma, Melanoma (Skin)
Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice
Prospective non-interventional study of clinical outcomes and biomarkers in patients with stage 0-IV skin melanoma in real clinical practice
- Conditions
- Melanoma, Melanoma (Skin), Melanoma, Uveal, Melanoma Stage IV
- Trial name
- ISABELLA (NCT05402059)
- Testing
- surgery (any volume) and / or pharmaceuticals treatment initiated or planned or only dynamic observation, in accordance with current clinical guidelines
- Where
- Russia
- Volunteers
- 1,570 people
- Sponsor
- MelanomaPRO, Russia
Malignant Melanoma
Study Of Zelboraf (Vemurafenib) in Patients With Locally-Advanced, Unresectable, Stage IIIc Or Metastatic Melanoma and Activating Exon 15 BRAF Mutations Other Than V600E
This is an open-label, multicenter, single-agent, phase II study of continuous oral Zelboraf (vemurafenib) in participants with locally-advanced, unresectable, stage IIIc or metastatic melanoma and activating exon 15 BRAF…
- Trial name
- NCT01586195
- Testing
- Vemurafenib
- Where
- 15 sites in United States
- Volunteers
- 31 people
- Sponsor
- Genentech, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.